The Goldman Sachs Group, Inc. 13D and 13G filings for Fate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 11:30 am Sale | 2025-06-30 | 13G | Fate Therapeutics, Inc. FATE | GOLDMAN SACHS GROUP INC GS | 2,274,020 2.000% | -6,213,200 (-73.21%) | Filing |
| 2025-05-09 12:27 pm Purchase | 2025-03-31 | 13G | Fate Therapeutics, Inc. FATE | GOLDMAN SACHS GROUP INC GS | 8,487,220 7.400% | 8,487,220 (New Position) | Filing |